Related Experiment Video
Updated: Jun 12, 2026

04:04
Asthma Detection Research Based on Voice Signal Processing and Machine Learning
Published on: July 22, 2025
Mean power frequency during speech in myalgia patients
E Suzuki1, S Ishigaki, H Yatani
1Department of Fixed Prosthodontics, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan.
Journal of Oral Rehabilitation
|May 25, 2010
Summary
Myalgia patients exhibit higher mean power frequency (MPF) in masseter muscles during speech compared to controls. This objective electromyogram (EMG) finding may help evaluate subjective muscle pain.
Area of Science:
- Biomedical Engineering
- Neuroscience
- Musculoskeletal Disorders
Background:
- Myofascial pain in the masseter muscles, known as myalgia, affects speech.
- Electromyography (EMG) measures muscle electrical activity.
- Mean Power Frequency (MPF) is an EMG analysis parameter reflecting muscle fiber characteristics.
Purpose of the Study:
- To investigate differences in masseter muscle MPF during speech between individuals with myalgia and healthy controls.
- To explore the potential of MPF as an objective measure for muscle pain.
Main Methods:
- Surface EMG of bilateral masseter muscles was recorded during speech tasks.
- EMG data were analyzed using a computer-based system to calculate MPF.
- MPF values were compared between the myalgia patient group (n=19) and the control group (n=20).
Main Results:
- The myalgia group demonstrated significantly higher average MPF during speech (214.06 Hz) compared to the control group (183.39 Hz).
- The difference in MPF between groups was statistically significant (P < 0.001).
- Higher MPF in myalgia patients may indicate altered motor unit recruitment or firing rates.
Conclusions:
- Speech-induced masseter muscle activity shows distinct MPF characteristics in individuals with myalgia.
- MPF analysis of EMG signals during speech presents a potential objective method for assessing subjective muscle pain.
- This research highlights a link between objective EMG measures and the subjective experience of muscle pain.
Related Concept Videos
Muscle Stimulation Frequency
The contraction strength of muscles is regulated by motor neurons, which modulate the frequency of action potentials dispatched to the motor units based on the body's requirements. This process of varying the muscle stimulation frequency allows muscles to contract with a force that is precisely tailored to the needs of the moment, whether lifting a feather or a heavy box.
Wave summation
At low firing rates, motor neurons induce individual twitch contractions in muscle fibers. These twitches...
Wave summation
At low firing rates, motor neurons induce individual twitch contractions in muscle fibers. These twitches...
Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

